In breast cancer, an HLA-A*O2-restricted TCR targeted p53R175H therapy from peripheral blood lymphocytes was infused into a patient, who experienced a partial response lasting 6 months [171]. The gene discussed is HLA-A; the disease is breast carcinoma.